Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease
Matthew Taylor, Dario R. Alessi
Current Opinion in Cell Biology (2020) Vol. 63, pp. 102-113
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Structural analysis of the full-length human LRRK2
Alexander Myasnikov, Hanwen Zhu, Patricia Hixson, et al.
Cell (2021) Vol. 184, Iss. 13, pp. 3519-3527.e10
Open Access | Times Cited: 157
LRRK2 and idiopathic Parkinson’s disease
Emily M. Rocha, Matthew T. Keeney, Roberto Di Maio, et al.
Trends in Neurosciences (2022) Vol. 45, Iss. 3, pp. 224-236
Open Access | Times Cited: 105
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding
Alexia F. Kalogeropulou, Elena Purlyte, Francesca Tonelli, et al.
Biochemical Journal (2022) Vol. 479, Iss. 17, pp. 1759-1783
Open Access | Times Cited: 87
Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy
Xiaoyan Gao, Tuo Yang, Ying Gu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 74
A blood-based marker of mitochondrial DNA damage in Parkinson’s disease
Rui Qi, Esther Sammler, Claudia P. González-Hunt, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 711
Open Access | Times Cited: 43
A STING–CASM–GABARAP pathway activates LRRK2 at lysosomes
Amanda Bentley‐DeSousa, Agnes Roczniak-Ferguson, Shawn M. Ferguson
The Journal of Cell Biology (2025) Vol. 224, Iss. 2
Open Access | Times Cited: 3
LRRK2 and the Endolysosomal System in Parkinson’s Disease
Madalynn L. Erb, Darren J. Moore
Journal of Parkinson s Disease (2020) Vol. 10, Iss. 4, pp. 1271-1291
Open Access | Times Cited: 81
Parkinson's: A Disease of Aberrant Vesicle Trafficking
Pawan Singh, Miratul M. K. Muqit
Annual Review of Cell and Developmental Biology (2020) Vol. 36, Iss. 1, pp. 237-264
Open Access | Times Cited: 72
RIPK protein kinase family: Atypical lives of typical kinases
Gregory D. Cuny, Alexei Degterev
Seminars in Cell and Developmental Biology (2020) Vol. 109, pp. 96-105
Open Access | Times Cited: 71
The 14-3-3 Proteins as Important Allosteric Regulators of Protein Kinases
Veronika Obšilová, Tomáš Obšil
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8824-8824
Open Access | Times Cited: 70
LRRK2 phosphorylation of Rab GTPases in Parkinson's disease
Suzanne R. Pfeffer
FEBS Letters (2022) Vol. 597, Iss. 6, pp. 811-818
Open Access | Times Cited: 42
LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition
Narayana Yadavalli, Shawn M. Ferguson
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 31
Open Access | Times Cited: 32
LRRK2 and Parkinson's disease: from genetics to targeted therapy
Yuri L. Sosero, Ziv Gan‐Or
Annals of Clinical and Translational Neurology (2023) Vol. 10, Iss. 6, pp. 850-864
Open Access | Times Cited: 30
Role of Autophagy Pathway in Parkinson’s Disease and Related Genetic Neurological Disorders
Christos Themistokleous, Enrico Bagnoli, Ramaa Parulekar, et al.
Journal of Molecular Biology (2023) Vol. 435, Iss. 12, pp. 168144-168144
Open Access | Times Cited: 29
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Jiarui Hu, Dan Zhang, Keyue Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115475-115475
Closed Access | Times Cited: 27
Pharmacology of LRRK2 with type I and II kinase inhibitors revealed by cryo-EM
Hanwen Zhu, Patricia Hixson, Wen Ma, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 15
Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity
Alexia F. Kalogeropulou, Jordana B. Freemantle, Paweł Lis, et al.
Biochemical Journal (2020) Vol. 477, Iss. 22, pp. 4397-4423
Open Access | Times Cited: 67
R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils
Ying Fan, Raja Sekhar Nirujogi, Alícia Garrido, et al.
Acta Neuropathologica (2021) Vol. 142, Iss. 3, pp. 475-494
Open Access | Times Cited: 52
Impact of Type II LRRK2 inhibitors on signaling and mitophagy
Anna Tasegian, François Singh, Ian G. Ganley, et al.
Biochemical Journal (2021) Vol. 478, Iss. 19, pp. 3555-3573
Open Access | Times Cited: 51
LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Dominika Wojewska, Arjan Kortholt
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1101-1101
Open Access | Times Cited: 44
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
Asad Malik, Athanasios Karapetsas, Raja Sekhar Nirujogi, et al.
Biochemical Journal (2021) Vol. 478, Iss. 3, pp. 553-578
Open Access | Times Cited: 41
Membrane remodeling properties of the Parkinson’s disease protein LRRK2
Xinbo Wang, Javier Espadas, Yumei Wu, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 43
Open Access | Times Cited: 17
Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B
Prosenjit Pal, Matthew Taylor, Yuko P. Y. Lam, et al.
Science Advances (2023) Vol. 9, Iss. 50
Open Access | Times Cited: 16
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
Caroline Benn, Lee A. Dawson
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 42
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors
Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 1, pp. 838-856
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top